About Prima Biomed
Prima Biomed is a publicly listed company based in Armadale (Australia) founded in 1987. Immunotherapeutics based on the LAG-3 immune control mechanism and dendritic cell therapy for cancer. Prima Biomed has completed 1 acquisition, including Immutep. Prima Biomed offers products and services including LAG-3 Immunotherapy and TACTI-004 Trial Asset. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Prima is focused on bringing immunotherapeutic products to the market. Its core technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The lead product, IMP321 is in clinical development for the treatment of a range of cancer indications. In addition, Prima has significantly developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission
- Headquarters Armadale, Australia
- Stage Public
- SectorsHealthcare
- Website primabiomed.com.au
- Social LinkedIn X Facebook YouTube
- Legal Name Immutep Limited
- Annual Revenue$10.03 M (USD)as on Jun 30, 2026
- Net Profit-$54.61 M (USD)-29.09as on Jun 30, 2026
- EBITDA-$56.07 M (USD)-20.31as on Jun 30, 2026
- Latest Funding Round$37.5M (USD), Post-IPO
Oct 2014
- Investors
- Investments & Acquisitions
Products & Services of Prima Biomed
Prima Biomed offers a comprehensive portfolio of products and services, including LAG-3 Immunotherapy and TACTI-004 Trial Asset.
Therapies that stimulate immune system to fight cancer effectively.
Phase III trial for non-small cell lung cancer immunotherapy.
Apps and channels of Prima Biomed
its YouTube channel Immutep has 186 subscribers and 30 videos.
Videos from Prima Biomed
The most watched videos on Prima Biomed's YouTube channel, Immutep (186 subscribers). Click a video to play it here.
More on Immutep.
Funding Insights of Prima Biomed
- Total Rounds 1
- Last Round Post-IPO — $37.5M
- First Round $37.5M
(Oct 2014)
- Investors Count 1
All 1 funding rounds of Prima Biomed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2014 | $37.5M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Prima Biomed
Prima Biomed has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Bergen Asset Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Bergen Asset Management is focused on global institutional investments. | bergenasset.com | Boca Raton, USA |
Investor details for Prima Biomed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Prima Biomed
Prima Biomed is a publicly listed company on the ASX with ticker symbol IMM in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Jun 1988
- Listed onASX: IMM
- Listed entityIMMUTEP LIMITED
- Exchange sectorHealth technology
- ISINAU000000IMM6
- Share price0.03 AUD (-3.85% on the day) · 2026-10-14
- Market capitalisation38,326,867.00 AUD
- EPS (diluted, trailing year)-0.05 AUD
- Volume (last session)9,183,279
Financials of Prima Biomed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 14.6M AUD | -79.3M AUD | -81.4M AUD |
| 2025 | -61.4M AUD | -67.7M AUD | |
| 2024 | -42.7M AUD | -48.1M AUD | |
| 2023 | -39.9M AUD | -42.9M AUD | |
| 2022 | 170,370 AUD | -32.2M AUD | -36.3M AUD |
Detailed financial statements for Prima Biomed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prima Biomed
Prima Biomed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immutep.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for autoimmune and oncology indications are developed. | immutep.com | Sydney, Australia | 2001 | Oct 2014 | $28M |
Complete acquisition details for Prima Biomed
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Prima Biomed
4 dated milestones of Prima Biomed across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Prima Biomed is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $37.5M.
- Acquisition Acquires Immutep.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prima Biomed
Complete news archive for Prima Biomed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prima Biomed
Prima Biomed was founded in 1987 and raised its 1st funding round 27 years after it was founded.
Prima Biomed is headquartered in Armadale, Australia. It is registered at Armadale, Victoria, Australia.
Annual revenue of Prima Biomed is $10.03M as on Jun 30, 2026.
Prima is focused on bringing immunotherapeutic products to the market. Its core technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The lead product, IMP321 is in clinical development for the treatment of a range of cancer indications. In addition, Prima has significantly developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission.
Prima Biomed offers LAG-3 Immunotherapy and TACTI-004 Trial Asset.
Yes, Prima Biomed is publicly traded on ASX under the ticker symbol IMM.
Prima Biomed has made 1 acquisition, including Immutep.
Prima Biomed has 1 investor. Key investors include Bergen Asset Management.